AstraZeneca has won a shareholder vote approving plans for the FTSE 100’s largest company to elevate its New York listing, in a blow to the London market.
A total of 99 per cent of voting shareholders backed the company’s proposal to list shares directly on the New York Stock Exchange, replacing the American depositary receipts that until now have given US investors exposure to the company.
The votes cast represented almost 80 per cent of the issued share capital. About 0.6 per cent of voting shareholders did not back the plans.
您已閱讀26%（532字），剩余74%（1547字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。